Mitochondria-mediated apoptosis in patients with adenocarcinoma of the breast: Correlation with histological grade and menopausal status

Breast

Volumn 20, Issue 1, 2011, Pages 86-92

  Vinothini, Govindarajah ^a   Murugan, Ramalingam Senthil ^a   Nagini, Siddavaram ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Apoptosis; Bcl 2; Breast cancer; Caspases; Menopausal status; Mitochondria

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 2; CASPASE 3; CASPASE 6; CASPASE 8; CASPASE 9; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1;

ADULT; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOCHONDRION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; WESTERN BLOTTING;

EID: 79451469350     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.08.002     Document Type: Article

References (57)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108.
2. Yeole B.B. Trends in cancer incidence in female breast, cervix uteri, corpus uteri, and ovary in India. Asian Pac J Cancer Prev 2008, 9:119-122.
3. Jemal A., Clegg L.X., Ward E., Ries L.A., Wu X., Jamison P.M., et al. Annual report to the nation on the status of cancer, 1975-2001 with a special feature regarding survival. Cancer 2004, 101:3-27.
4. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M. Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 2000, 124:966-978.
5. Parton M., Dowsett M., Smith I. Studies of apoptosis in breast cancer. BMJ 2001, 322:1528-1532.
6. Wodarz D., Komarova N. Can loss of apoptosis protect against cancer?. Trends Genet 2007, 23:232-237.
7. Burz C., Berindan-Neagoe I., Balacescu O., Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol 2009, 9:1-11.
8. Brunelle J.K., Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009, 122:437-441.
9. Rupinder S.K., Gurpreet A.K., Manjeet S. Cell suicide and caspases. Vascul Pharmacol 2007, 46:383-393.
10. Wong W.W., Puthalakath H. Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway. IUBMB Life 2008, 60:390-397.
11. Yip K.W., Reed J.C. Bcl-2 family proteins and cancer. Oncogene 2008, 27:6398-6406.
12. Ghavami S., Hashemi M., Ande S.R., Yeganeh B., Xiao W., Eshraghi M.C., et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009, 46:497-510.
13. Thomadaki H., Talieri M., Scorilas A. Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett 2007, 247:48-55.
14. Bukholm I.R., Bukholm G., Nesland J.M. Reduced expression of both Bax and Bcl-2 is independently associated with lymph node metastasis in human breast carcinomas. APMIS 2002, 110:214-220.
15. Nadler Y., Camp R.L., Giltnane J.M., Moeder C., Rimm D.L., Kluger H.M., et al. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 2008, 10:R35.
16. Kymionis G.D., Dimitrakakis C.E., Konstadoulakis M.M., Arzimanoglou I., Leandros E., Chalkiadakis G., et al. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?. J Surg Res 2001, 99:161-168.
17. Elston C.W., Ellis I.O. Assessment of histological grade. The breast 1998, 356-384. Churchill Livingstone, Edinburgh, New York. 3rd ed. C.W. Elston, O. Ellis (Eds.).
18. Legrand-Poels S., Schoonbrodt S., Piette J. Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem J 2000, 349:765-773.
19. Johnson D., Lardy H. Isolation of liver or kidney mitochondria. Methods Enzymol 1967, 10:94-96.
20. Vinothini G., Senthil Murugan R., Nagini S. Evaluation of molecular markers in a rat model of mammary carcinogenesis. Oncol Res 2009, 17:483-493.
21. Chipuk J.E., Green D.R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol 2008, 18:157-164.
22. Adams J.M., Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001, 26:61-66.
23. Petros A.M., Olejniczak E.T., Fesik S.W. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004, 1644:83-94.
24. Krajewski S., Bodrug S., Krajewska M., Shabaik A., Gascoyne R., Berean K., et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995, 146:1309-1319.
25. Zhuang L., Lee C.S., Scolyer R.A., McCarthy S.W., Zhang X.D., Thompson J.F., et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007, 20:416-426.
26. Itoh T., Itoh A., Pleasure D. Bcl-2-related protein family gene expression during oligodendroglial differentiation. J Neurochem 2003, 85:1500-1512.
27. Lisenn Lalier L., Francois Cartron P., Juin P., Nedelkina S., Manon S. Bax activation and mitochondrial insertion during apoptosis. Apoptosis 2007, 12:887-896.
28. Camisasca D.R., Honorato J., Bernardo V., da Silva L.E., da Fonseca E.C., de Faria P.A., et al. Expression of Bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. Oral Oncol 2009, 45:225-233.
29. Casado S., Forteza J., Dominguez S., Abad M.T., Perez I., Intxaurbe I., et al. Predictive value of P53, BCL-2, and BAX in advanced head and neck carcinoma. Am J Clin Oncol 2002, 25:588-590.
30. Brotin E., Meryet-Figuière M., Simonin K., Duval R.E., Villedieu M., Leroy-Dudal J., et al. Bcl-x(L) and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer 2010, 126:885-895.
31. Rochaix P., Krajewski S., Reed J.C., Bonnet F., Voigt J.J., Brousset P. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis. J Pathol 1999, 187:410-415.
32. Kumaraguruparan R., Karunagaran D., Balachandran C., Manohar B.M., Nagini S. Of humans and canines: a comparative evaluation of heat shock and apoptosis-associated proteins in mammary tumors. Clin Chim Acta 2006, 365:168-176.
33. Vinothini G., Balachandran C., Nagini S. Evaluation of molecular markers in canine mammary tumours: correlation with histological grading. Oncol Res 2009, 8:193-201.
34. Yang L., Zhu X., Ran L. Correlations of HER-2, PCNA, Bcl-2, and Bax expression to prognosis of breast cancer. Ai Zheng 2007, 26:756-761.
35. O'Driscoll L., Cronin D., Kennedy S.M., Purcell R., Linehan R., Glynn S., et al. Expression and prognostic relevance of Mcl-1 in breast cancer. Anticancer Res 2004, 24:473-482.
36. Sjöström-Mattson J., Von Boguslawski K., Bengtsson N.O., Mjaaland I., Salmenkivi K., Blomqvist C. The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer. Acta Oncol 2009, 48:1137-1143.
37. Martínez-Arribas F., Martín-Garabato E., Zapardiel I., Sánchez J., Lucas A., Tejerina A.R. Bax expression in untreated breast cancer: an immunocytometric study of 255 cases. Anticancer Res 2008, 28:2595-2598.
38. Gasparini G., Barbareschi M., Doglioni C., Palma P.D., Mauri F.A., Boracchi P., et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995, 1:189-198.
39. Veronese S., MaurIifa Csffo O., Scaioli M., Aldovini D., Perrone G., Galligioni E., et al. Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int J Cancer 1998, 79:13-18.
40. Alireza A., Raheleh S., Abbass R., Mojgan M., Mohamadreza M., Gholamreza M., et al. An immunohistochemistry study of tissue bcl-2 expression and its serum levels in breast cancer patients. Ann N Y Acad Sci 2008, 1138:114-120.
41. Ding Q., He X., Xia W., Hsu J.M., Chen C.T., Li L.Y., et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 2007, 67:4564-4571.
42. Campioni M., Santini D., Tonini G., Murace R., Dragonetti E., Spugnini E.P., et al. Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol 2005, 14:811-818.
43. Zlobec I., Minoo P., Baker K., Haegert D., Khetani K., Tornillo L., et al. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer 2007, 43:1101-1107.
44. Leo C., Richter C., Horn L.C., Schütz A., Pilch H., Höckel M. Expression of Apaf-1 in cervical cancer correlates with lymph node metastasis but not with intratumoral hypoxia. Gynecol Oncol 2005, 97:602-606.
45. Guo Y., Srinivasula S.M., Druilhe A., Fernandes-Alnemri T., Alnemri E.S. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 2002, 277:13430-13437.
46. Micheau O., Thome M., Schneider P., Holler N., Tschopp J., Nicholson D.W., et al. The long form of FLIP is an activator of caspase-8 at the Fas death inducing signaling complex. J Biol Chem 2002, 277:45162-45171.
47. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
48. Jiang Z.H., Wu J.Y. Alternative splicing and programmed cell death. Proc Soc Exp Biol Med 1999, 220:64-72.
49. Porter A.G., Janicke R.U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999, 6:99-104.
50. Slee E.A., Adrain C., Martin S.J. Executioner caspase-3, -6, and -7 performs distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 2001, 276:7320-7326.
51. Soung Y.H., Lee J.W., Kim S.Y., Jang J., Park Y.G., Park W.S., et al. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res 2005, 65:815-821.
52. Devarajan E., Sahin A.A., Chen J.S., Krishnamurthy R.R., Aggarwal N., Brun A.M., et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002, 21:8843-8851.
53. Soung Y.H., Lee J.W., Kim S.Y., Park W.S., Nam S.W., Lee J.Y., et al. Mutational analysis of proapoptotic caspase-9 gene in common human carcinomas. APMIS 2006, 114:292-297.
54. Soung Y.H., Lee J.W., Kim S.Y., Park W.S., Nam S.W., Lee J.Y., et al. Somatic mutations of CASP3 gene in human cancers. Hum Genet 2004, 115:112-115.
55. Yang X.F., Xin Y., Mao L.L. Clinicopathological significance of PTEN and caspase-3 expressions in breast cancer. Chin Med Sci J 2008, 23:95-102.
56. Nassar A., Sexton D., Cotsonis G., Cohen C. Survivin and caspase-3 expressions in breast carcinoma: correlation with apoptosis and prognosis. Appl Immunohistochem Mol Morphol 2008, 16:221-226.
57. Chunder N., Mandal S., Basu D., Roy A., Roychoudhury S., Panda C.K. Deletion mapping of chromosome 1 in early onset and late onset breast tumours- a comparative study in eastern India. Pathol Res Pract 2003, 199:313-321.